SCHEMBL3468673

SCHEMBL3468673

O=C1c2ccccc2C(=O)N1CCCCCCCCCCCCCCCCCCCCCCO

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.70
ALDH1A1 P00352 2/20 0.70
MEN1 O00255 2/20 0.70
KMT2A Q03164 2/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
RGS12 O14924 1/20 0.70
NPC1 O15118 1/20 0.70
LMNA P02545 1/20 0.70
PABPC1 P11940 1/20 0.70
HTT P42858 1/20 0.70
RECQL P46063 1/20 0.70
RAB9A P51151 1/20 0.70
TDP1 Q9NUW8 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
HDAC8 Q9BY41 3/20 0.61
HDAC3 O15379 2/20 0.61
HDAC4 P56524 2/20 0.61
HDAC1 Q13547 2/20 0.61
HDAC7 Q8WUI4 2/20 0.61
HDAC2 Q92769 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3468337 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7544499 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7352888 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7285741 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL7296911 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4179085 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL17275126 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1448490 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1162502 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1703575 1.00 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2261662-B1 Novel synthetic blocking reagents FORSCHUNGSZENTRUM BORSTEL LEIBNIZ ZENTRUM FUER MEDIZIN UND BIOWISSENSCHAFTEN (DE) 2014-01-22 EP disclosed
US-8501199-B2 Synthetic blocking reagents FORSCHUNGSZENTRUM BORSTEL (DE) 2013-08-06 US disclosed
US-20100317048-A1 NOVEL SYNTHETIC BLOCKING REAGENTS FORSCHUNGSZENTRUM BORSTEL (DE) 2010-12-16 US disclosed
EP-2261662-A1 Novel synthetic blocking reagents Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften (DE) 2010-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317048-A1 NOVEL SYNTHETIC BLOCKING REAGENTS SPR, SSB, LY96 KDM4E 1490/4885ALDH1A1 3115/4885MEN1 4078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.